Paper390559
Ribavirin: an antiviral agent.
Sidwell RW and 2 others. Pharmacol Ther, 1979. Cited by 117 papers, by iCite.
Cite this record
ConductScience Library. Ribavirin: an antiviral agent. Papers, record 390559. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/390559
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antiviral Agents | Major topic |
| Ribavirin | Major topic |
| Ribonucleosides | Major topic |
| Animals | |
| Antineoplastic Agents | |
| Autoimmune Diseases | |
| Bacteria | |
| Hepatitis | |
| Humans | |
| Immunosuppressive Agents | |
| Plant Viruses |
Source PubMed
Cited by27
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 117 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40718474 | Screening and Identification of Multiple Peptides Homologous to the Fusion Glycoprotein Gc of Schmallenberg Virus Able to Inhibit Viral Infection. | Transbound Emerg Dis | 2025 | https://conductscience.org/library/papers/40718474 | PubMed |
| 40519175 | Bandavirus dabieense: A review of epidemiology, clinical characteristics, pathophysiology, treatment and prevention. | Virulence | 2025 | https://conductscience.org/library/papers/40519175 | PubMed |
| 40050867 | Antiviral treatment for viral pneumonia: current drugs and natural compounds. | Virol J | 2025 | https://conductscience.org/library/papers/40050867 | PubMed |
| 37250214 | New 1,3,4-thiadiazoles as potential anticancer agents: pro-apoptotic, cell cycle arrest, molecular modelling, and ADMET profile. | RSC Adv | 2023 | https://conductscience.org/library/papers/37250214 | PubMed |
| 36851554 | Biochemistry of the Respiratory Syncytial Virus L Protein Embedding RNA Polymerase and Capping Activities. | Viruses | 2023 | https://conductscience.org/library/papers/36851554 | PubMed |
| 36766795 | Immunomodulation of Natural Killer Cell Function by Ribavirin Involves TYK-2 Activation and Subsequent Increased IFN-γ Secretion in the Context of In Vitro Hepatitis E Virus Infection. | Cells | 2023 | https://conductscience.org/library/papers/36766795 | PubMed |
| 36464706 | Small molecules in the treatment of COVID-19. | Signal Transduct Target Ther | 2022 | https://conductscience.org/library/papers/36464706 | PubMed |
| 32571182 | Molecular Targets in the Chemotherapy of Coronavirus Infection. | Biochemistry (Mosc) | 2020 | https://conductscience.org/library/papers/32571182 | PubMed |
| 32287578 | Chapter 3 Antiviral drugs: general considerations. | Perspect Med Virol | 1985 | https://conductscience.org/library/papers/32287578 | PubMed |
| 31641088 | Attenuation of Live-Attenuated Yellow Fever 17D Vaccine Virus Is Localized to a High-Fidelity Replication Complex. | mBio | 2019 | https://conductscience.org/library/papers/31641088 | PubMed |
| 27152039 | Clinical presentation and management of suspected ribavirin toxicosis in a dog. | Can Vet J | 2016 | https://conductscience.org/library/papers/27152039 | PubMed |
| 21989310 | Pharmacological and biological antiviral therapeutics for cardiac coxsackievirus infections. | Molecules | 2011 | https://conductscience.org/library/papers/21989310 | PubMed |
| 21058912 | Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever. | Clin Infect Dis | 2010 | https://conductscience.org/library/papers/21058912 | PubMed |
| 18822145 | Neuraminidase activity provides a practical read-out for a high throughput influenza antiviral screening assay. | Virol J | 2008 | https://conductscience.org/library/papers/18822145 | PubMed |
| 16043507 | Ribavirin is not a functional mimic of the 7-methyl guanosine mRNA cap. | RNA | 2005 | https://conductscience.org/library/papers/16043507 | PubMed |
| 15733013 | Peginterferon alpha-2a (40KD) plus ribavirin: a review of its use in the management of patients with chronic hepatitis C and persistently 'normal' ALT levels. | Drugs | 2005 | https://conductscience.org/library/papers/15733013 | PubMed |
| 12656650 | Peginterferon-alpha-2a (40kD) plus ribavirin: a review of its use in the management of chronic hepatitis C. | Drugs | 2003 | https://conductscience.org/library/papers/12656650 | PubMed |
| 11827565 | Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C. | Drugs | 2002 | https://conductscience.org/library/papers/11827565 | PubMed |
| 10792198 | The single dose pharmacokinetics of ribavirin in subjects with chronic liver disease. | Br J Clin Pharmacol | 2000 | https://conductscience.org/library/papers/10792198 | PubMed |
| 7533301 | Picornavirus inhibitors. | Pharmacol Ther | 1994 | https://conductscience.org/library/papers/7533301 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/390559
GET https://conductscience.org/api/papers/v1/390559/cited_by?page=2